Elixirgen Therapeutics to Present New Data Showing Successful Ex Vivo Telomere Elongation with EXG-34217 in a Phase 1/2 Clinical Trial at the 64th ASH Annual Meeting
BALTIMORE, November 7, 2022 — Elixirgen Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapies using its controllable self-replicating RNA (c-srRNA) platform, today announced an oral presentation of new data showing successful ex vivo telomere elongation with lead asset, EXG-34217 (autologous CD34+ hematopoietic stem cells that have been treated […]